CN104922178B - Hypoglycemic effervescent tablet and application thereof - Google Patents
Hypoglycemic effervescent tablet and application thereof Download PDFInfo
- Publication number
- CN104922178B CN104922178B CN201510323099.3A CN201510323099A CN104922178B CN 104922178 B CN104922178 B CN 104922178B CN 201510323099 A CN201510323099 A CN 201510323099A CN 104922178 B CN104922178 B CN 104922178B
- Authority
- CN
- China
- Prior art keywords
- parts
- fruit powder
- yellow
- powder
- effervescent tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an effervescent tablet for reducing blood sugar, which is prepared from the following raw and auxiliary materials in parts by weight: 5-85 parts of Nitraria sibirica pall powder, 2-4 parts of citric acid, 3-5 parts of fumaric acid, 12-15 parts of fructo-oligosaccharide, 15-35 parts of sorbitol and 2-10 parts of sodium bicarbonate. The invention also provides a preparation method and application of the effervescent tablet. The research of the invention finds that the yellow spine fruit powder has good blood sugar reducing function, can increase the insulin quantity, has the blood sugar reducing effect equivalent to that of a first-line chemical medicament of diabetes mellitus, namely glibenclamide, but is different from the first-line chemical medicament of diabetes mellitus, the yellow spine fruit powder does not cause liver damage, has good safety and wider application range, and is more suitable for being used as food, health care products or medicaments for treating and preventing diabetes mellitus.
Description
Technical Field
The invention belongs to the field of health care products, and particularly relates to a hypoglycemic effervescent tablet taking yellow spine fruit powder as a raw material and application thereof.
Technical Field
According to statistics, the number of people suffering from diabetes in China currently reaches 9240 ten thousands, which is the first to live all over the world (Yang W, et al. N Engl J Med, 2010, 362 (12): 1090-1101). The treatment cost of diabetes in China is up to 1734 billion yuan each year, and the direct medical expenses caused by diabetes already account for 13 percent of the total medical expenses in China (Alcorn T, et al. Lancet, 2012, 379 (9833): 2227-2228). Therefore, diabetes not only seriously harms people's health, but also brings a heavy economic burden to the nation. Therefore, the prevention and treatment of diabetes are not easy.
Yellow thorn, Berberis darysiachyan maxim of berberidaceae, is a traditional wild berry which is used as medicine and food for minority nationalities such as Mongolian, Tibetan and Uygur just like white thorn and sea buckthorn (black thorn), and is called as Qinghai three thorns. The Qinghai handbook of commonly used Chinese herbal medicines has detailed records of the cortex xanthil (namely root bark): the cortex Prinsepiae utilis is the bark of Berberis Amurensis Dunn of berberidaceae, which is a dicotyledonous plant drug. The medical function of the fruit is briefly described, and the fruit has the functions of treating abdominal pain, dyspepsia, abdominal distension, dysentery and the like.
At present, the blood sugar reduction of the yellow thorn fruits is not reported.
Disclosure of Invention
The invention aims to provide a hypoglycemic effervescent tablet based on yellow thorn. The invention also aims to provide a preparation method and application of the tablet.
Specifically, the invention provides a hypoglycemic effervescent tablet, which is prepared from the following raw and auxiliary materials in parts by weight:
5-85 parts of Nitraria sibirica pall powder, 2-4 parts of citric acid, 3-5 parts of fumaric acid, 12-15 parts of fructo-oligosaccharide, 15-35 parts of sorbitol and 2-10 parts of sodium bicarbonate.
Further, the beverage also comprises 1-5 parts by weight of edible essence, 0.5-1.5 parts by weight of aspartame and 0.1-0.6 part by weight of magnesium stearate.
Wherein the yellow thorn fruit powder is prepared by one of the following methods:
the method comprises the following steps: drying the yellow thorn fruits, and crushing to obtain yellow thorn fruit powder;
the second method comprises the following steps: squeezing fructus Xanthii, filtering, and drying to obtain fructus Xanthii powder;
the third method comprises the following steps: taking the yellow thorn fruits, extracting by taking water as a solvent, and drying an extracting solution to obtain the yellow thorn fruit powder.
Wherein the yellow thorn is Berberis darysi Dasysstachya Maxim.
The invention also provides a preparation method of the hypoglycemic effervescent tablet, which comprises the following operation steps:
(1) taking raw and auxiliary materials according to the proportion;
(2) mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
The invention also provides application of the effervescent tablet in preparing medicines, health-care products or foods for reducing blood sugar.
Wherein the medicine, health-care product or food is a medicine, health-care product or food for preventing or treating type I and type II diabetes mellitus or/and diabetic complication.
Further, the drug, health product or food is a drug, health product or food for preventing or treating a patient whose liver function is normal or impaired.
The research of the invention finds that the yellow thorn fruit can not cause the liver function to be damaged, and is also suitable for treating the diabetic with damaged liver function.
Wherein the medicine, health product or food is a medicine, health product or food for increasing insulin level.
Further, the medicine, health-care product or food is a medicine, health-care product or food for improving lipid metabolism disorder of diabetic patients.
The research of the invention finds that the yellow spine fruit powder has good functions of reducing blood sugar and blood fat, can increase insulin quantity, has the effect of reducing blood sugar equivalent to that of a first-line chemical medicament of diabetes, namely glibenclamide, but is different from the first-line chemical medicament of diabetes, has the advantages of no liver damage, good safety and wider application range, and is more suitable for being used as food, health care products or medicaments for treating and preventing diabetes.
The research of the invention finds that the fruit powder has overlarge specific surface area, is easy to absorb moisture and is not suitable for storage and production; and the flowability is not good, so that the production and the packaging are not convenient. In view of the above situation, the invention prepares the yellow spine fruit powder into tablets, which is convenient for the storage, transportation and packaging of the product, has good taste and is convenient for patients to use.
Detailed Description
Example 1 preparation of xanthorrhiza fruit powder effervescent tablets:
the effervescent tablet is prepared from the following components in percentage by weight:
85g of yellow spine fruit powder, 2-4 g of citric acid, 3-5 g of fumaric acid, 12g of fructo-oligosaccharide, 15g of sorbitol, 2-10 g of sodium bicarbonate, 1-5 g of edible essence, 0.5-1.5 g of aspartame and 0.1-0.6 g of magnesium stearate.
The specific method comprises the following steps:
mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
Preparing the yellow thorn fruit powder: drying the yellow thorn fruits, and crushing to obtain the yellow thorn fruit powder.
Example 2 preparation of xanthorrhiza fruit powder effervescent tablets:
the effervescent tablet is prepared from the following components in percentage by weight:
50g of yellow spine fruit powder, 20-40 g of citric acid, 30-50 g of fumaric acid, 150g of fructo-oligosaccharide, 350g of sorbitol, 20-100 g of sodium bicarbonate, 10-50 g of edible essence, 5-15 g of aspartame and 1-6 g of magnesium stearate.
The specific method comprises the following steps:
mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
Preparing the yellow thorn fruit powder: drying the yellow thorn fruits, and crushing to obtain the yellow thorn fruit powder.
Example 3 preparation of xanthorrhiza fruit powder effervescent tablets:
the effervescent tablet is prepared from the following components in percentage by weight:
50g of yellow spine fruit powder, 2-4 g of citric acid, 3-5 g of fumaric acid, 14g of fructo-oligosaccharide, 26g of sorbitol, 2-10 g of sodium bicarbonate, 1-5 g of edible essence, 0.5-1.5 g of aspartame and 0.1-0.6 g of magnesium stearate.
The specific method comprises the following steps:
mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
Preparing the yellow thorn fruit powder: squeezing fructus Xanthii, filtering, and drying to obtain fruit powder.
Example 4 preparation of xanthorrhiza fruit powder effervescent tablets:
the effervescent tablet is prepared from the following components in percentage by weight:
65g of yellow spine fruit powder, 2-4 g of citric acid, 3-5 g of fumaric acid, 13g of fructo-oligosaccharide, 27g of sorbitol, 2-10 g of sodium bicarbonate, 1-5 g of edible essence, 0.5-1.5 g of aspartame and 0.1-0.6 g of magnesium stearate.
The specific method comprises the following steps:
mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
Preparing the yellow thorn fruit powder: taking the yellow thorn fruits, adding water for extraction, and drying the extracting solution to obtain the fruit powder.
Example 5 preparation of xanthorrhiza fruit powder effervescent tablets:
the effervescent tablet is prepared from the following components in percentage by weight:
30g of yellow spine fruit powder, 2-4 g of citric acid, 3-5 g of fumaric acid, 15g of fructo-oligosaccharide, 15g of sorbitol, 2-10 g of sodium bicarbonate, 1-5 g of edible essence, 0.5-1.5 g of aspartame and 0.1-0.6 g of magnesium stearate.
The specific method comprises the following steps:
mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
Preparing the yellow thorn fruit powder: taking the yellow thorn fruits, adding water for extraction, and drying the extracting solution to obtain the fruit powder.
Example 6 pharmacodynamic study of the Nitraria sibirica pall powder of the present invention
1) Experimental drugs: drying the yellow thorn fruits, and crushing to obtain the yellow thorn fruit powder. The dosage is calculated according to the weight of the rat, and the low dosage and the high dosage after gastric lavage are respectively 0.4g/kg and 1.6g/kg (based on the dosage of the yellow spine fruit powder).
2) Animals: four-week-old Kunming rat, male, normal grade, 135g, provided by Gansu Chinese medicine college. Experiments were carried out after one week of rearing in cages placed in the laboratory (8 per cage, temperature 22. + -. 1 ℃ C., humidity 42%. + -. 2%). The method comprises the following five groups: the test results are respectively a blank group (no model is made by citric acid buffer solution for intravenous injection, and the stomach is filled with ultrapure water), a model group (STZ model is made by tail vein injection, and the stomach is filled with ultrapure water), a positive medicine group (STZ model is made by tail vein injection, and glibenclamide is filled with 20 mg/kg), a low-dose group (STZ model is made by tail vein injection, and the stomach is filled with xanthorrhiza fruit powder is 0.4g/kg), and a high-dose group (STZ model is made by tail vein injection, and the stomach is filled with xanthorrhiza fruit powder is 1.6 g/kg). The molding method comprises the following steps: fasting is carried out for 16h in advance, then, the blood glucose is measured after 60mg/kg of tail vein injection of STZ (prepared by citric acid buffer solution) and 72 hours after injection, and whether the model is successful or not is tested.
3) Experimental reagent: 95% medical alcohol, Nanjing Ning's chemical reagent, Inc.; physiological saline, Shandong Qi Du pharmaceutical Co., Ltd; cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, lipoprotein esterase, liver esterase kit, Nanjing is established into biotechnology limited company.
4) An experimental instrument: Bio-Rad680 microplate reader, Burle, USA; DS-1 type tissue homogenizer, Shanghai Zhenghui Industrial and trade Co., Ltd; TGL-16G-A type tubular centrifuge, Shanghai' an pavilion scientific Instrument factory; UV-722N visible ultraviolet spectrophotometer, Shanghai Nicke, Inc.; HD type constant temperature water bath, Liaoyang city constant temperature instrument factory.
5) The experimental process comprises the following steps: 40 healthy SD rats are randomly divided into 5 groups according to body weight, namely a blank group, a model group, a positive medicine group and low and high dose groups. Distilled water was administered to the blank group and the model group by gavage every day; the positive medicine group is administrated with glibenclamide for 1 time per day; feeding the fructus Hippophae powder to the tested groups by intragastric administration for 1 time every day, and continuously feeding six groups for 28 days; simultaneously, measuring insulin and blood sugar every 7 days; after the test substance is administered at the last time, blood is taken from carotid artery after anesthesia, and the obtained blood is centrifuged to obtain supernatant for detecting blood lipid index, glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase. After death, rat liver tissues are taken, surface bloodstains are washed by normal saline, the rat liver tissues are sucked dry by using filter paper, a tissue homogenizer is used for homogenizing, homogenate liquid is collected into a centrifuge tube and is centrifuged for 10min at 3000rpm, and supernatant liquid is sucked for carrying out the activity determination of lipoprotein esterase and liver esterase.
6) Determination of blood sugar reduction of yellow thorn fruit powder in rats with diabetes and results thereof
TABLE 1 Effect of yellow thorn fruit powder on STZ induced blood glucose in rats (Mean + -SD)
Note: group comparison with Normal groupap is less than 0.05; comparison with formation of modulesbp＜0.05；
TABLE 2 Effect of yellow Nitraria fruit powder on STZ-induced insulin in rats (Mean + -SD)
Note: group comparison with Normal groupap is less than 0.05; comparison with formation of modulesbp＜0.05；
As can be seen from tables 1 and 2, the yellow thorn fruits can effectively reduce the blood sugar of the rat with the STZ diabetes mellitus and increase the insulin quantity, and the effect is equivalent to that of a positive medicament, which indicates that the yellow thorn fruits can be used for treating the diabetes mellitus.
7) Determination of blood lipid reduction of blood lipid in diabetic rats by using Nitraria sibirica pall powder and results thereof
STZ-induced diabetes causes nuclear pyknosis, and vitreogenesis of rat islet cells. Its lipid metabolism is then disturbed. At the same time, the lipid metabolism of the rat is disordered, and related blood lipid indexes and enzyme activities related to the lipid metabolism are also disordered.
TABLE 3 Effect of yellow thorn fruit powder on STZ induced cholesterol TC, triglyceride TG, HDL, LDL of rats (Mean + -SD)
Note: comparison with Normal groupap is less than 0.05; comparison with formation of modulesbp＜0.05
As can be seen from Table 3, the low and high dose group of the yellow spine fruit powder of the present invention has the effects of regulating and reducing cholesterol, triglyceride and low density lipoprotein of STZ-induced diabetic rats, and regulating and increasing high density lipoprotein. And the dose effect relationship is shown, and the high dose group and the model group have significant difference (p is less than 0.05). Meanwhile, experiments show that the effect of the high-dose group is equivalent to that of glibenclamide, and the glibenclamide, as a chemically synthesized medicine, has certain side effect on organisms, so that natural plants, namely the yellow thorn fruit powder, are suggested to be used as a substitute for health care products.
HL is an extracellular protein which is synthesized by hepatic parenchymal cells, has the activity of phosphorus A1 and glycerol triacetate hydrolase and plays an important role in plasma lipid transport, and is mainly involved in the reconstruction of HDL-C, the metabolism of chylomicron debris and low-density lipoprotein and the reverse transport of cholesterol. The HL activity abnormality has higher correlation with atherosclerosis and diabetes. LPL is a key enzyme for lipoprotein metabolism and is a key enzyme for hydrolyzing glycerol triacetate in the triglyceride-rich casein. Its main function is to hydrolyze glycerol triacetate in CM and VLDL to glycerol and fatty acids. Lipoprotein esterase LPL and liver esterase HL can decompose triglyceride TG and into glycerol and free fatty acid FFA, and the activity of lipoprotein esterase and liver esterase can be calculated by measuring the free fatty acid produced by decomposition with a copper reagent.
Under the stimulation of some medicines, liver tissues in the body of AST and ALT are infiltrated by fat cells to influence the activity of relevant liver cell enzymes, and generally, simvastatin, glibenclamide and the like have certain influence on the liver tissues.
TABLE 4 Effect of xanthorrhizos sibirica fruit powder on STZ-induced lipoprotein esterase LPL, hepatic esterase HL, glutamic-oxaloacetic transaminase AST and glutamic-pyruvic transaminase ALT in rats (Mean + -SD)
Note: comparison with Normal groupap is less than 0.05; comparison with formation of modulesbp is less than 0.05; compared with the normal groupcp＜0.05.
The yellow spine fruit powder can increase the activity of HL and LPL of experimental rats, and the LPL is a rate-limiting enzyme for removing TG-rich lipoprotein, thereby playing an important role in lipoprotein circulation. Meanwhile, the HL activity of the diabetic rat can be increased, so that the HL is used as a ligand to promote liver cells to take up cholesterol and chylomicron remnant, the concentration of total cholesterol and glycerol triacetate in blood plasma is reduced, and the effect of regulating the lipid metabolism disorder of the body is achieved.
Compared with the glibenclamide positive medicine group, the AST and ALT activities are reduced to different degrees, which shows that the positive medicine group has the effect of damaging the liver, while the yellow spine fruit powder has no effect of damaging the liver and has obvious difference.
Claims (6)
1. An effervescent tablet for reducing blood sugar, which is characterized in that: the medicament is prepared from the following raw and auxiliary materials in parts by weight:
5-85 parts of Nitraria sibirica pall powder, 2-4 parts of citric acid, 3-5 parts of fumaric acid, 12-15 parts of fructo-oligosaccharide, 15-35 parts of sorbitol and 2-10 parts of sodium bicarbonate;
the yellow thorn is Berberis darysiachyan Maxim of berberidaceae;
the yellow thorn fruit powder is prepared by the following method: drying the yellow thorn fruits, and crushing to obtain the yellow thorn fruit powder.
2. An effervescent tablet for reducing blood sugar, which is characterized in that: the medicament is prepared from the following raw and auxiliary materials in parts by weight:
5-85 parts of yellow spine fruit powder, 2-4 parts of citric acid, 3-5 parts of fumaric acid, 12-15 parts of fructo-oligosaccharide, 15-35 parts of sorbitol, 2-10 parts of sodium bicarbonate, 1-5 parts of edible essence, 0.5-1.5 parts of aspartame and 0.1-0.6 part of magnesium stearate;
the yellow thorn is Berberis darysiachyan Maxim of berberidaceae;
the yellow thorn fruit powder is prepared by the following method: drying the yellow thorn fruits, and crushing to obtain the yellow thorn fruit powder.
3. A process for preparing hypoglycemic effervescent tablets as claimed in claim 2, wherein: the method comprises the following operation steps:
(1) taking raw and auxiliary materials according to the proportion;
(2) mixing fructus Xanthii powder, citric acid, and fumaric acid, and granulating; mixing fructo-oligosaccharide, sorbitol, sodium bicarbonate, edible essence, and aspartame, and granulating; drying the two granules, mixing, adding magnesium stearate, and tabletting to obtain effervescent tablet.
4. Use of the tablet according to claim 1 or 2 for the preparation of a medicament for lowering blood glucose.
5. Use according to claim 4, characterized in that: the medicine is a medicine for preventing or treating type I and type II diabetes or/and diabetic complications.
6. Use according to claim 4 or 5, characterized in that: the medicine is used for improving lipid metabolism disorder of diabetic patients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510323099.3A CN104922178B (en) | 2015-06-09 | 2015-06-09 | Hypoglycemic effervescent tablet and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510323099.3A CN104922178B (en) | 2015-06-09 | 2015-06-09 | Hypoglycemic effervescent tablet and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104922178A CN104922178A (en) | 2015-09-23 |
| CN104922178B true CN104922178B (en) | 2021-05-11 |
Family
ID=54109833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510323099.3A Active CN104922178B (en) | 2015-06-09 | 2015-06-09 | Hypoglycemic effervescent tablet and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104922178B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553489B (en) * | 2018-03-23 | 2021-04-27 | 青海大学 | Effervescent tablet for improving dyslipidemia and application thereof |
| CN115105482A (en) * | 2022-07-13 | 2022-09-27 | 山东哲成生物科技有限公司 | Effervescent tablet for reducing microalbuminuria and preparation method and application thereof |
| CN116236527B (en) * | 2022-09-08 | 2024-06-25 | 梅州市南方金柚研究院 | Honey pomelo effervescent tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1260131A (en) * | 1999-09-20 | 2000-07-19 | 青海省青藏高原生物制品有限公司 | Reddish beautycherry jam |
| CN1362070A (en) * | 2000-12-30 | 2002-08-07 | 中国科学院西北高原生物研究所 | Composite medicine for treating hyperlipemia |
-
2015
- 2015-06-09 CN CN201510323099.3A patent/CN104922178B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1260131A (en) * | 1999-09-20 | 2000-07-19 | 青海省青藏高原生物制品有限公司 | Reddish beautycherry jam |
| CN1362070A (en) * | 2000-12-30 | 2002-08-07 | 中国科学院西北高原生物研究所 | Composite medicine for treating hyperlipemia |
Non-Patent Citations (1)
| Title |
|---|
| 柴达木白刺研究现状与发展趋势;索有瑞等;《青海科技》;20060225(第01期);第20-23页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104922178A (en) | 2015-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| CN104922178B (en) | Hypoglycemic effervescent tablet and application thereof | |
| US20160199427A1 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN105030984B (en) | A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN104069365A (en) | Applications of dendrobium polyphenol on liver protection and diabetes treatment/prevention | |
| CN102697781B (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
| CN1305405C (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| CN104352624B (en) | Application of the anaesthetic core fragrant plant n-butanol extract in preventing and treating diabetes medicament is prepared | |
| KR101094157B1 (en) | The health food for improvement of glucosuria using madisin-materials of plants | |
| CN103800352A (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| CN103815397B (en) | Downgrade food compositions of blood pressure, blood fat and blood sugar and preparation method thereof | |
| KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
| CN104983770B (en) | Blood sugar reducing tablet and application thereof | |
| CN104922180B (en) | Blood sugar reducing capsule and application thereof | |
| CN105999195B (en) | Preparation method of ginseng branch poria cocos preparation | |
| KR101407889B1 (en) | Fraxinus rhynchophylla Hance extracts compositions for treating or preventing inflammatory diseases | |
| KR101113603B1 (en) | Extract composition of herbal mixture for improving liver fucntion and relieving hangover | |
| CN105920051B (en) | Flammulina velutipes extract and preparation method and application thereof | |
| CN104957308B (en) | A kind of Antrodia camphorata tea | |
| CN106822338A (en) | Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof | |
| KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN106942439B (en) | Cyclocarya paliurus and guava leaf blood glucose reducing tea and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |